Cell division

Orphan designation: Upifitamab rilsodotin Treatment of ovarian cancer, 09/12/2022 Positive

Retrieved on: 
Thursday, April 18, 2024
Community, Diagnosis, Civil service commission, Ovarian cancer, Cell death, Prevalence, Cell division, Disease, Clinical, Patient, Committee, EMA, IRIS, Agency, European, COMP, European Commission, Marketing, Medicine, Pharmaceutical industry

Overview

Key Points: 
  • Overview
    This medicine was designated as an orphan medicine for the treatment of ovarian cancer in the European Union on 9 December 2022.
  • All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
  • Upifitamab rilsodotin is composed of an antibody that binds NaPi2b and a drug called AF-HPA which prevents cell division, resulting in cell death.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Plant Growth Regulators Markets: Cytokinins, Auxins, Gibberellins, Ethylene, Abscisic Acid - Global Forecast to 2031 - Increasing Need for Sustainable Agricultural Practices - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 3, 2024
Agriculture, Natural Resources, Environmental Health, Environment, Climate Change, Promoter, Farmer, Growth, Cell division, Powder, Cytokinin, Vegetable, Risk, Plant, SWOT analysis, Food security, Abscisic acid, Cereal, Investment, Fruit, Plant hormone, Soil, Government

In 2024, Europe is expected to account for the largest share of the plant growth regulators market.

Key Points: 
  • In 2024, Europe is expected to account for the largest share of the plant growth regulators market.
  • Based on type, the plant growth regulators market is segmented into cytokinins, auxins, gibberellins, ethylene, abscisic acid, and other types.
  • Based on function, the plant growth regulators market is segmented into plant growth promoters and plant growth inhibitors.
  • The plant growth promoters segment is expected to account for the larger share of the plant growth regulators market in 2024.

Eternity Biotech Launches Crowdfunding Campaign on Wefunder to Accelerate Anti-Aging Product Development

Retrieved on: 
Tuesday, April 2, 2024
DNA repair, Gene, The Company, DNA, Research, Growth, Cell division, Apoptosis, Regulation CF

NEW YORK, April 2, 2024 /PRNewswire/ -- Eternity Biotech, Inc. (the "Company", "Eternity"), a biotechnology company dedicated to finding solutions for longer, healthier lives, today announced the launch of a crowdfunding campaign on Wefunder to advance its anti-aging product development.

Key Points: 
  • NEW YORK, April 2, 2024 /PRNewswire/ -- Eternity Biotech, Inc. (the "Company", "Eternity"), a biotechnology company dedicated to finding solutions for longer, healthier lives, today announced the launch of a crowdfunding campaign on Wefunder to advance its anti-aging product development.
  • After replicating these results in human cells, Eternity looks to develop this technology and identify a novel candidate in the anti-aging space.
  • "With this campaign, we look to usher in a new era of growth and development for Eternity and within the broader anti-aging sector of life science research," said Joseph Hernandez, Chairman and Chief Executive Officer of Eternity.
  • To learn more about Eternity's technology and participate in this campaign, visit Eternity's page on Wefunder .

Making Long-Term Memories Requires Nerve-Cell Damage

Retrieved on: 
Wednesday, March 27, 2024
Inflammation, Radulović, Psychiatry, Brain, TLR9, COVID, Gene, DNA repair, DSM-IV codes, Cell division, Genome instability, University Medical Center, Infection, Memory, Organelle, Hippocampus, Mouse, DNA, Albert Einstein, Nature, Cancer, Toll-like receptor 9, Neuron, Northwestern University, Doctor of Philosophy, Alzheimer's disease, Genome, Aarhus University, Cytoplasm, Cell, Dominic, B.A, Encephalitis, Ageing, Vaccine

"But our findings suggest that inflammation in certain neurons in the brain's hippocampal region is essential for making long-lasting memories."

Key Points: 
  • "But our findings suggest that inflammation in certain neurons in the brain's hippocampal region is essential for making long-lasting memories."
  • But looking more closely, we found, to our surprise, that TLR9 was activated only in clusters of hippocampal cells that showed DNA damage."
  • But in this population of hippocampal neurons, the DNA damage appeared to be more substantial and sustained.
  • Importantly, the researchers found that blocking the TLR9 inflammatory pathway in hippocampal neurons not only prevented mice from forming long-term memories but also caused profound genomic instability, i.e, a high frequency of DNA damage in these neurons.

Pioneering Technique Reveals New Layer of Human Gene Regulation

Retrieved on: 
Friday, February 9, 2024
Human, NYU Langone Health, RNA, Chromatin, Tick, Cell division, Cancer, Howard Hughes Medical Institute, IIS, DNA repair, Genetic code, Bangladesh Technical Education Board, Protein, NYU, RNA polymerase II, Multimedia, DNA, Genome, Biochemistry, Gene expression, Pharmacology, Gene, Bacteria, National Institutes of Health, Ageing, Doctor of Philosophy, Disease, Vaccine

Now a new study led by Nudler's team at NYU Langone Health reveals that their new technique, Long Range Cleavage sequencing (LORAX-seq), can directly detect where backtracking events begin and end.

Key Points: 
  • Now a new study led by Nudler's team at NYU Langone Health reveals that their new technique, Long Range Cleavage sequencing (LORAX-seq), can directly detect where backtracking events begin and end.
  • The results also suggest that persistent backtracking occurs frequently throughout genomes, happens more often near certain gene types, and has functions well beyond DNA repair.
  • "If further work expands our findings to different developmental programs and pathological conditions, backtracking may be akin to epigenetics, the discovery of which revealed a surprising new layer of gene regulation without changing the DNA code."
  • Locked, backtracked complexes are less likely to be rescued by TFIIS-driven cleavage, and more likely to delay transcription of the gene involved.

ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)

Retrieved on: 
Monday, February 5, 2024
MYCN, Toxicity, SAN, Neoplasm, NCI, Glomus tumor, SN-38, DNA, Cmax, SLFN11, Clinical trial, Gene, Biomarker, Cell division, Patient, Safety, Irinotecan, Pros, Central nervous system, MYC, PEGylation, CNS, Phase, Medulloblastoma, TTY, Cancer, Bangladesh Technical Education Board, Ependymoma, Pharmaceutical industry

National Institutes of Health’s NCI investigators Dr. Marta Penas-Prado and Dr. Mark Gilbert are conducting the trial.

Key Points: 
  • National Institutes of Health’s NCI investigators Dr. Marta Penas-Prado and Dr. Mark Gilbert are conducting the trial.
  • High levels of MYC drive oncogenesis in many cancers and induce DNA changes leading to the formation of “topoisome complexes”.
  • The NCI trial will assess whether PLX038 is safe and efficacious in primary CNS tumors driven by MYC or MYCN amplifications.
  • For patients interested in enrolling in this clinical trial, please call NCI’s toll-free number: 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615); visit the website: https://trials.cancer.gov; and/or email: [email protected].

Global CDC7 Kinase Inhibitors Clinical Trials & Market Insight Report 2024 Featuring Carna Biosciences, Chia Tai Tianqing Pharma, Eli Lilly, Memorial Sloan-Kettering Cancer Center, and Schrodinger - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 11, 2024
Health, Oncology, Clinical Trials, Other Health, DNA virus, Cell division, Patient, Mitosis, Indication, DNA replication, Research, Viral, Radiation, DNA, S phase, DNA repair, DBF4, Cancer, Cell proliferation, CDC7, Cell death, Virus, Inflammation, VP3

The "Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering.
  • The uncontrolled proliferation of cancer cells often involves dysregulation of DNA replication, and CDC7 kinase is often overexpressed in various cancer types.
  • In contrast, CDC7 kinase inhibitors focus on disrupting DNA replication process, offering a more specific and potentially less toxic approach.
  • Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024 Report Highlights:
    Global CDC7 Kinase Inhibitors Clinical Pipeline By Company, Indication & Phase

Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 21, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Marketing, Hypothyroidism, INN, Woman, Progression-free survival, Nausea, Syndrome, Heart, Cancer, Inflammation, Skull, Proteinuria, Anatomy, Cell division, IIA, Diarrhea, Fatigue, ATC, Capsule, Bleeding, Pancreas, RET, VEGF, FGFR, Cerebral edema, Neoplasm, Stroke, Enzyme, Liver failure, Safety, Kidney cancer, Arthralgia, Heart failure, Patient, Urine, Medical Subject Headings, Stomatitis, Immune system, Everolimus, International, Encephalopathy, Language, Somatic symptom disorder, Blood, Mouth, Catherine Disher, Select, Medicine, Vomiting, Pembrolizumab, Cholesterol, PDGF, Kidney failure, Weight loss, Headache, KIT, Brain, Acral lentiginous melanoma, Swelling, Hypoesthesia, Splenic infarction, Confusion, European Medicines Agency, RCC, Kidney, Growth, Sunitinib, Hypercholesterolemia, Rash, Medical device

Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Marketing, Platinum, INN, Risk, HER2, Leukopenia, Heartburn, Woman, BRCA, Man, Nausea, DNA, Cancer, Neoplasm, Mutation, Pancreatic cancer, ADP, Prostate, Anatomy, Cell division, Cough, IIA, Diarrhea, Prostate cancer, HRD, Fatigue, Breast cancer, ATC, Platelet, Pancreas, Prednisone, Disease, Genome, Abdomen, Testosterone, PARP, Neutrophil, Bevacizumab, Appetite, Human, Anemia, Patient, Medical Subject Headings, Peritoneum, International, FIGO, Tubing (recreation), Neutropenia, Language, Castration, Dizziness, Thrombocytopenia, BRCA1, Gene, Tablet, Select, Time, Vomiting, Ovary, Prednisolone, X-ray, Ovarian cancer, Headache, BRCA2, European Medicines Agency, Indigestion, Periodic breathing, Birth control

Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

POLIVY (Polatuzumab Vedotin-piiq) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032: Focus on 7MM - United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023
Biotechnology, General Health, Pharmaceutical, Health, MMAE, Apoptosis, Research, Immunoglobulin G, ADC, Clinical trial, SWOT, EU4, Microtubule, Polatuzumab vedotin, Roche, CD79B, Cell division, NHL, Fine chemical, Risk management, Vaccine, Pharmaceutical industry, DLBCL

This report provides comprehensive insights about POLIVY for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets.

Key Points: 
  • This report provides comprehensive insights about POLIVY for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets.
  • The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
  • Further, it also consists of future market assessments inclusive of the POLIVY market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.
  • What are the other emerging products available and how are these giving competition to POLIVY for DLBCL?